These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 34187062)

  • 1. Nonfactor Therapies: New Approaches to Prophylactic Treatment of Haemophilia.
    Chowdary P
    Hamostaseologie; 2021 Aug; 41(4):247-256. PubMed ID: 34187062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical considerations for nonfactor-replacement therapies in the treatment of haemophilia with inhibitors.
    Jiménez-Yuste V; Auerswald G; Benson G; Dolan G; Hermans C; Lambert T; Ljung R; Morfini M; Santagostino E; Zupančić Šalek S
    Haemophilia; 2021 May; 27(3):340-350. PubMed ID: 33742707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prophylaxis in patients with haemophilia complicated by inhibitors].
    Paweł Ł
    Pol Merkur Lekarski; 2011 Mar; 30(177):211-4. PubMed ID: 21545000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.
    Valentino LA
    Haemophilia; 2010 Mar; 16(2):263-71. PubMed ID: 20028421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The current status of prophylactic replacement therapy in children and adults with haemophilia.
    Ljung R; Gretenkort Andersson N
    Br J Haematol; 2015 Jun; 169(6):777-86. PubMed ID: 25819695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
    Dodd C; Watts RG
    Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.
    Mahlangu JN
    BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations.
    Perry D; Berntorp E; Tait C; Dolan G; Holme PA; Laffan M; Lassila R; Mumford A; Pasi J; Wilde J; Will A; Yee TT
    Haemophilia; 2010 Jan; 16(1):80-9. PubMed ID: 19780845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The past and future of haemophilia: diagnosis, treatments, and its complications.
    Peyvandi F; Garagiola I; Young G
    Lancet; 2016 Jul; 388(10040):187-97. PubMed ID: 26897598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current options and new developments in the treatment of haemophilia.
    Wong T; Recht M
    Drugs; 2011 Feb; 71(3):305-20. PubMed ID: 21319868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventing bleeds by treatment: new era for haemophilia changing the paradigm.
    Marijke van den Berg H
    Haemophilia; 2016 Jul; 22 Suppl 5():9-13. PubMed ID: 27405669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2017 Clinical trials update: Innovations in hemophilia therapy.
    Hartmann J; Croteau SE
    Am J Hematol; 2016 Dec; 91(12):1252-1260. PubMed ID: 27563744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey.
    Zappa S; McDaniel M; Marandola J; Allen G
    Haemophilia; 2012 May; 18(3):e140-53. PubMed ID: 22533455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression.
    Treur MJ; McCracken F; Heeg B; Joshi AV; Botteman MF; De Charro F; Van Hout B
    Haemophilia; 2009 Mar; 15(2):420-36. PubMed ID: 19335751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
    Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
    N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice.
    Franchini M; Mannucci PM
    Br J Clin Pharmacol; 2011 Oct; 72(4):553-62. PubMed ID: 21204915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A history of prophylaxis in haemophilia.
    Moreno MM; Cuesta-Barriuso R
    Blood Coagul Fibrinolysis; 2019 Mar; 30(2):55-57. PubMed ID: 30507712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haemophilia: factoring in new therapies.
    Fassel H; McGuinn C
    Br J Haematol; 2021 Sep; 194(5):835-850. PubMed ID: 34322873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for individualizing haemophilia care.
    Sørensen B; Auerswald G; Benson G; Elezović I; Felder M; Lambert T; Morfini M; Remor E; Salaj P; Santagostino E; Šalek SZ; Ljung R
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):849-57. PubMed ID: 25396764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.